glp 1 receptor agonist GLP-1 Agonists as Treatments for Type 2 Diabetes GLP-1 Receptor Agonist Market Growth

Volume 78

The research and development costs required to bring a new product to market are substantial with no guarantee that the product will ever become profitable

[DOI] [PubMed] [Google Scholar] 79.Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, Noel RA, Braun DK, Bloomgren GL

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Future incretin-based therapies Future research in incretin-based treatment of overweight and obesity aims to investigate the potential of combining GLP-1-R agonism with the targeting of other peptide hormones to achieve synergistic effects, with the most prominent targets of interest being the GIPR, the glucagon receptor (GCGR) and the amylin receptor [16]